Galapagos NV expected to post a loss of 96 cents a share - Earnings Preview

Lakefront Biotherapeutics NV

31/10/2023 11:10

* Galapagos NV  GLPG.AS   is expected to show a fall in
quarterly
revenue when it reports  results on November 2. 
    * The Malines (mechelen) Antwerpen-based  company is
expected to
report  a 39.7% decrease in revenue to €82.15 million from
€136.2 million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Galapagos NV is for
a
loss of 96 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 11
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Galapagos
NV is
€41​, above​ its last closing price of €31.09. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.71       -0.83      0.08      Beat    109.6
  2023                                0.35              
 Dec. 31 2022  -0.53       -0.53      -3.16     Missed  -490.7
                                                        ​
 Sep. 30 2022  -0.80       -0.80      0.33      Beat    141.3
 ​​Jun.        -0.87       -0.82      -0.29     Beat    64.5
 30 2022                                                
 Mar. 31 2022  -1.06       -1.06      -0.20     Beat    81.1​
 Dec. 31 2021  -0.75       -0.64      0.25      Beat    138.9
 Sep. 30 2021  -1.33       -1.31      -0.99     Beat    24.2
 This summary was machine generated October 31 at 11:10 GMT.  All
figures in euros  unless otherwise stated